The neutrophil-to-albumin ratio (NAR), a novel inflammatory biomarker combining absolute neutrophils count and albumin, has been used to assess the prognosis of various diseases, including aneurysmal subarachnoid hemorrhage [15-17], hemorrhagic stroke [18], lung cancer [19, 20], rectal cancer [21], colorectal cancer [22], and non-alcoholic fatty liver disease [23]. The gene discussed is ALB; the disease is lung cancer.